Early observations and pilot data that first suggested a new direction
Anti-TNF agents revolutionized IBD treatment. The ACCENT I trial established infliximab maintenance therapy for Crohn disease, with 573 patients showing that scheduled infliximab maintained remission in 39-45% at week 30 versus 21% with placebo (p≤0.003). The ACT 1 and ACT 2 trials extended these findings to ulcerative colitis, demonstrating clinical response rates of 61-69% versus 29-37% with placebo at week 8 among 728 patients. These landmark trials established the biologic therapy era for IBD.
Landmark RCTs and pivotal trials that established the evidence base
New biologic mechanisms expanded treatment options. The GEMINI 1 trial validated vedolizumab, a gut-selective anti-integrin, for UC in 895 patients, achieving 47.1% clinical response vs 25.5% placebo at week 6 (p<0.001). The UNITI program demonstrated ustekinumab efficacy in Crohn disease: UNITI-1 (741 patients, anti-TNF failures) and UNITI-2 (628 patients, conventional therapy failures) showed superior response rates with ustekinumab at week 6, and the IM-UNITI maintenance study confirmed 53.1% remission at week 44 with 8-weekly dosing versus 35.9% with placebo.
Follow-up studies, subgroup analyses, and real-world validation
The OCTAVE program introduced the first oral small molecule therapy for UC, tofacitinib (a JAK inhibitor). Among 1,139 induction patients and 593 maintenance patients, tofacitinib achieved remission in 16.6-18.5% at week 8 (vs 3.6-8.2% placebo) and 34.3-40.6% at week 52 (vs 11.1% placebo). This represented a fundamentally different therapeutic approach—oral, non-immunogenic, and with rapid onset—but required careful safety consideration given subsequent JAK inhibitor class-level cardiovascular and malignancy signals.
Integration into clinical practice guidelines and recommendations
AGA and ECCO guidelines evolved to support mechanism-based biologic selection considering disease phenotype, severity, prior treatment failure, and safety profile. Anti-TNF agents remained first-line biologics for most patients, with vedolizumab preferred for UC given its gut-selective safety profile, ustekinumab for Crohn disease particularly after anti-TNF failure, and JAK inhibitors as an option for UC with appropriate cardiovascular risk assessment.
AGA
Biologic selection based on disease type, severity, prior treatment, and safety profile; anti-TNF first-line for most; vedolizumab and ustekinumab for specific phenotypes or anti-TNF failures
ECCO
Mechanism-based selection; early biologic use for high-risk patients; combination therapy with immunomodulators for anti-TNF optimization
Now
Current standard of care and ongoing research directions
IBD biologic selection has evolved from a limited anti-TNF paradigm to a rich therapeutic landscape including anti-integrins, anti-IL-12/23, anti-IL-23, JAK inhibitors, and S1P modulators. The field increasingly emphasizes early intervention, treat-to-target strategies with objective biomarker monitoring, and precision medicine approaches including therapeutic drug monitoring. Head-to-head comparisons (like VARSITY for vedolizumab vs adalimumab in UC) are informing direct treatment comparisons. The expanding pipeline includes novel targets and combination approaches.
Five main mechanism classes: anti-TNF (infliximab, adalimumab), anti-integrin (vedolizumab), anti-IL-12/23 (ustekinumab), anti-IL-23 (risankizumab, guselkumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod, etrasimod). Selection depends on disease type, severity, prior treatment, comorbidities, and safety profile.
How does vedolizumab differ from anti-TNF agents?+
Vedolizumab is gut-selective, blocking alpha4beta7 integrin to prevent lymphocyte trafficking to the gut without systemic immunosuppression. In GEMINI 1, it achieved 47.1% clinical response vs 25.5% placebo at week 6 for UC. Its gut-selective mechanism confers a favorable safety profile, making it preferred for patients with infection risk or malignancy concerns.
